CANCER PATIENTS ARE GETTING MORE DRUG THAN NECESSARY AND PAYING MORE THAN NECESSARY
RESEARCH IN INDIA HAS EVEN FOUND THAT ONE-TWELFTH OF THE STANDARD NIVOLUMAB DOSE MAY BE EFFECTIVE.
DRUGMAKERS, HOSPITALS, AND PHYSICIANS HAVE FINANCIAL INCENTIVES TO MAINTAIN HIGHER DOSING
ONE ESTIMATE SUGGESTS THE U.S. COULD HAVE SAVED ROUGHLY $31 BILLION IN 2024 BY USING THE LOWEST EFFECTIVE DOSES OF 29 EXPENSIVE CANCER DRUGS.
